Faeth Therapeutics, Inc. Increase (Decrease) in Employee Related Liabilities
Faeth Therapeutics, Inc. (FTH) reported Increase (Decrease) in Employee Related Liabilities of -$108.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-04
- Faeth Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was -$2.75M, a 5016.07% decline year-over-year.
- Faeth Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was $2.65M.
- Faeth Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $164.00K, a 70.29% decline year-over-year.
- Faeth Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was $381.00K, a 21.12% decline year-over-year.
- Faeth Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2025 was -$562.00K, a 184.38% decline from fiscal 2024.
- Faeth Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2024 was $666.00K.
- Faeth Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2023 was -$650.00K, a 191.68% decline from fiscal 2022.
- Faeth Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2022 was $709.00K, a 15.29% decline from fiscal 2021.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$108.00K 10-Q · filed 2026-08-04 | $56.00K derived: sum of 3 quarters · filed 2026-08-04 | $437.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.65M 10-Q · filed 2026-05-15 | $2.81M derived: sum of 2 quarters · filed 2026-05-15 | $3.19M derived: sum of 3 quarters · filed 2026-05-15 | $3.25M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $164.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $545.00K derived: sum of 2 quarters · filed 2026-03-30 | $601.00K derived: sum of 3 quarters · filed 2026-08-04 | -$562.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $381.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $437.00K derived: sum of 2 quarters · filed 2026-08-04 | -$726.00K 10-Q · filed 2025-11-14 | -$174.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$1.11M 10-Q · filed 2026-08-04 | -$555.00K derived: sum of 3 quarters · filed 2026-08-04 | -$72.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$1.16M 10-Q · filed 2026-05-15 | -$611.00K derived: sum of 2 quarters · filed 2026-05-15 | -$128.00K derived: sum of 3 quarters · filed 2026-05-15 | $206.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $552.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.03M derived: sum of 2 quarters · filed 2026-03-30 | $1.37M derived: sum of 3 quarters · filed 2026-03-30 | $666.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $483.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $817.00K derived: sum of 2 quarters · filed 2025-11-14 | $114.00K 10-Q · filed 2025-11-14 | $531.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $334.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$369.00K 10-Q · filed 2025-08-05 | $48.00K derived: sum of 3 quarters · filed 2025-08-05 | $426.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$703.00K 10-Q · filed 2025-05-06 | -$286.00K derived: sum of 2 quarters · filed 2025-05-06 | $92.00K derived: sum of 3 quarters · filed 2025-05-06 | $224.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $795.00K derived: sum of 2 quarters · filed 2025-03-28 | $927.00K derived: sum of 3 quarters · filed 2025-03-28 | -$650.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $378.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $510.00K derived: sum of 2 quarters · filed 2024-11-14 | -$1.07M 10-Q · filed 2024-11-14 | -$367.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.45M 10-Q · filed 2024-08-06 | -$745.00K derived: sum of 3 quarters · filed 2024-08-06 | -$1.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$1.58M 10-Q · filed 2024-05-09 | -$877.00K derived: sum of 2 quarters · filed 2024-05-09 | -$133.00K derived: sum of 3 quarters · filed 2024-05-09 | $325.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.44M derived: sum of 2 quarters · filed 2024-02-29 | $1.90M derived: sum of 3 quarters · filed 2024-02-29 | $709.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $744.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.20M derived: sum of 2 quarters · filed 2023-11-07 | $9.00K 10-Q · filed 2023-11-07 | $147.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $458.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$735.00K 10-Q · filed 2023-08-03 | -$597.00K derived: sum of 3 quarters · filed 2023-08-03 | -$78.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$1.19M 10-Q · filed 2023-05-09 | -$1.05M derived: sum of 2 quarters · filed 2023-05-09 | -$536.00K derived: sum of 3 quarters · filed 2023-05-09 | $119.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $657.00K derived: sum of 2 quarters · filed 2023-03-29 | $1.31M derived: sum of 3 quarters · filed 2023-03-29 | $837.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $519.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.17M derived: sum of 2 quarters · filed 2022-11-08 | $699.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $655.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $180.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | -$475.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$271.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |